ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, announced the publication of a ...

The NCCN Guidelines are comprehensive, evidence-based recommendations to support the prevention, diagnosis, and treatment of more than 97% of cancers affecting patients in the United States. They are ...

Please provide your email address to receive an email when new articles are posted on . Previously granted FDA breakthrough device designation in January 2020, ColoSense is the “first noninvasive ...

Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous ...

The US Food and Drug Administration (FDA) has approved ColoSense (Geneoscopy, Inc), a multitarget stool RNA (mt-sRNA) test for colorectal cancer (CRC) screening in adults aged 45 or older who are at ...

A University of Liverpool study has used advanced genetic and genomic techniques to offer a major step forward in understanding and diagnosing infectious intestinal diseases. The research is published ...

About The Study: This study found that comparable levels of sensitivity and specificity as reported for the multitarget stool RNA (mt-sRNA) test in the colorectal cancer (CRC)-PREVENT study could be ...

A stool test is a diagnostic procedure that involves analyzing fecal matter, or poop, to check for signs of infection, inflammation, or disease. The specific analysis depends on a person’s symptoms ...

Parents may soon be able to determine whether their young child has autism by using a new stool test kit developed by researchers at the Chinese University of Hong Kong. The test, which analyzes gut ...